Development and evaluation of 4-(pyrrolidin-3-yl)benzonitrile derivatives as inhibitors of lysine specific demethylase 1.
Authors
Mould, Daniel PBremberg, U
Jordan, Allan M
Geitmann, M
McGonagle, Alison E
Somervaille, Tim C P
Spencer, Gary J
Ogilvie, Donald J
Affiliation
Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX,Issue Date
2017-10-15
Metadata
Show full item recordAbstract
As part of our ongoing efforts to develop reversible inhibitors of LSD1, we identified a series of 4-(pyrrolidin-3-yl)benzonitrile derivatives that act as successful scaffold-hops of the literature inhibitor GSK-690. The most active compound, 21g, demonstrated a Kd value of 22nM and a biochemical IC50 of 57nM. In addition, this compound displayed improved selectivity over the hERG ion channel compared to GSK-690, and no activity against the related enzymes MAO-A and B. In human THP-1 acute myeloid leukaemia cells, 21g was found to increase the expression of the surrogate cellular biomarker CD86. This work further demonstrates the versatility of scaffold-hopping asa method to develop structurally diverse, potent inhibitors of LSD1.Citation
Development and evaluation of 4-(pyrrolidin-3-yl)benzonitrile derivatives as inhibitors of lysine specific demethylase 1. 2017, 27 (20):4755-4759 Bioorg Med Chem LettJournal
Bioorganic & Medicinal Chemistry LettersDOI
10.1016/j.bmcl.2017.08.052PubMed ID
28927796Type
ArticleLanguage
enISSN
1464-3405ae974a485f413a2113503eed53cd6c53
10.1016/j.bmcl.2017.08.052
Scopus Count
Collections
Related articles
- Development of 5-hydroxypyrazole derivatives as reversible inhibitors of lysine specific demethylase 1.
- Authors: Mould DP, Bremberg U, Jordan AM, Geitmann M, Maiques-Diaz A, McGonagle AE, Small HF, Somervaille TCP, Ogilvie D
- Issue date: 2017 Jul 15
- Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
- Authors: Duan Y, Qin W, Suo F, Zhai X, Guan Y, Wang X, Zheng Y, Liu H
- Issue date: 2018 Dec 15
- Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
- Authors: Duan YC, Guan YY, Zhai XY, Ding LN, Qin WP, Shen DD, Liu XQ, Sun XD, Zheng YC, Liu HM
- Issue date: 2017 Jan 27
- Discovery of novel tranylcypromine-indazole-based derivatives as LSD1 inhibitors for acute myeloid leukemia treatment.
- Authors: Huang MJ, Liu Q, Song J, Gao B, Zhang S, Huang L
- Issue date: 2025 May 5
- Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1.
- Authors: Mould DP, Alli C, Bremberg U, Cartic S, Jordan AM, Geitmann M, Maiques-Diaz A, McGonagle AE, Somervaille TCP, Spencer GJ, Turlais F, Ogilvie D
- Issue date: 2017 Oct 12